Page 104 - Demo

Chapter 510238. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408, doi:10.1006/meth.2001.1262.39. Barra, W.F.; Moreira, F.C.; Pereira Cruz, A.M.; Khayat, A.S.; Calcagno, D.Q.; Carneiro Dos Santos, N.P.; Mascarenhas Junior, R.W.; Thomaz Araujo, T.M.; Ishak, G.; Demachki, S., et al. GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity. Oncotarget 2017, 8, 104286-104294, doi:10.18632/oncotarget.22216.40. Campomenosi, P.; Gini, E.; Noonan, D.M.; Poli, A.; D%u2019Antona, P.; Rotolo, N.; Dominioni, L.; Imperatori, A. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. Bmc Biotechnology 2016, 16, doi:ARTN 6010.1186/s12896-016-0292-7.41. Mathe, E.A.; Nguyen, G.H.; Bowman, E.D.; Zhao, Y.; Budhu, A.; Schetter, A.J.; Braun, R.; Reimers, M.; Kumamoto, K.; Hughes, D., et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009, 15, 6192-6200, doi:10.1158/1078-0432.CCR-09-1467.42. Leidner, R.S.; Ravi, L.; Leahy, P.; Chen, Y.; Bednarchik, B.; Streppel, M.; Canto, M.; Wang, J.S.; Maitra, A.; Willis, J., et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett%u2019s esophageal carcinogenesis. Genes Chromosomes Cancer 2012, 51, 473-479, doi:10.1002/gcc.21934.43. Zhou, J.; Song, S.; He, S.; Zhu, X.; Zhang, Y.; Yi, B.; Zhang, B.; Qin, G.; Li, D. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med 2014, 33, 950-956, doi:10.3892/ijmm.2014.1638.44. Avan, A.; Narayan, R.; Giovannetti, E.; Peters, G.J. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016, 7, 352-369, doi:10.5306/wjco.v7.i5.352.45. Essakly, A.; Loeser, H.; Kraemer, M.; Alakus, H.; Chon, S.H.; Zander, T.; Buettner, R.; Hillmer, A.M.; Bruns, C.J.; Schroeder, W., et al. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. Transl Oncol 2020, 13, 157-164, doi:10.1016/j.tranon.2019.10.013.46. Zhou, N.; Qu, Y.; Xu, C.; Tang, Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med 2016, 11, 625-630, doi:10.3892/etm.2015.2920.47. Garajov%u00e1, I.; Giovannetti, E.; Caponi, S.; van Zweeden, A.; Peters, G.J. MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer. Current Pharmacology Reports 2015, 1, 223-233, doi:10.1007/s40495-014-0008-4.48. Zhang, X.L.; Shi, H.J.; Wang, J.P.; Tang, H.S.; Cui, S.Z. MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol 2015, 8, 6397-6406.49. Beckett, E.L.; Yates, Z.; Veysey, M.; Duesing, K.; Lucock, M. The role of vitamins and minerals in modulating the expression of microRNA. Nutr Res Rev 2014, 27, 94-106, doi:10.1017/S0954422414000043.50. Wilke, H.; Muro, K.; Van Cutsem, E.; Oh, S.C.; Bodoky, G.; Shimada, Y.; Hironaka, S.; Sugimoto, N.; Lipatov, O.; Kim, T.Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014, 15, 1224-1235, doi:10.1016/S1470-2045(14)70420-6.